Phylogix, Inc. and Large Scale Biology Corporation have formed a bioprocessing alliance to develop and manufacture Phylogix, Inc.’s lead therapeutic protein, a native protein in hyacinth seeds called FRIL.
The protein represents a novel chemoprotective agent that, in animals, has demonstrated a unique ability to protect normal tissues from the toxic side effects of chemotherapy.
LSBC‘s Owensboro, Kentucky biomanufacturing facility will grow the hyacinth plants in the field and greenhouse, then harvest and purify the active ingredient for projected clinical trials.
At LSBC’s Vacaville headquarters, President John D. Fowler called the new alliance “doubly significant, both for the revenue opportunity it represents for LSBC and the commercial validation of our large-scale capabilities to manufacture and purify plant proteins using our proprietary technology.”
“We are delighted to be working with LSBC, a world leader in large-scale biomanufacturing of proteins in plants. Entering into an alliance with LSBC to manage the agronomics and manufacture our lead drug candidate brings Phylogix closer to its goal of developing a drug to improve the health and quality of life for chemotherapy patients,” said Phylogix President, Jeffrey G. Moore, Ph.D. Phylogix, Inc. is a privately held biotechnology company developing a novel class of therapeutics designed to protect and repair tissues damaged by chemotherapy.
Large Scale Biology uses its functional genomics, proteomics, and biomanufacturing technologies to develop and manufacture personalized drugs, vaccines and diagnostics for rapid identification and effective treatment of disease.